Skip to content
Screener

Hawkins HWKN Pharmaceutical — Revenue

Other product segments

Manufactured, blended or repackaged products
$185.9M+4.6%
Nutrition
$37.06M+4.9%
Bulk products
$28.9M
Agricultural
$27.91M+30.0%
Food
$24.31M-6.8%
Other
$4.63M+38.2%

Similar metrics at other companies

Kiniksa Pharmaceuticals International, plc logo
KNSAPharmaceutical — Revenue
$243.6M+55.4%
Zoetis logo
ZTSOther pharmaceutical — Revenue
$168M-4.0%
Zoetis logo
ZTSOther Non Pharmaceuticals — Revenue
$70M+2.9%
AMP
AMPHFinished Pharmaceutical Products — Revenue
$183.9M+5.4%
Cardinal Health logo
CAHPharmaceutical and Specialty Solutions — Revenue
$56.11B+11.3%
Gyre Therapeutics, Inc. logo
GYREGyre Pharmaceuticals — Revenue
$29.1M+8.7%

Other financials

Income statement

See full
Revenue$315.7M+7.6%
Gross profit$74.0M+2.3%
Operating income$38.7M-6.4%
Net income$37.3M+27.9%
EPS (diluted)$1.35-3.6%

Balance sheet

See full
Cash & equivalents$8.0M-45.0%
Total debt$260.7M-15.6%
Total equity$548.2M+13.1%
Total assets$1.0B+1.8%

Cash flow

See full
Operating cash flow$35.2M+11.6%
CapEx$11.6M-14.3%
Free cash flow$23.5M+31.2%

Valuation

See full
Market cap$2.71B-23.8%
Enterprise value$2.97B-23.0%
P/E30.3×-11.8×
P/S2.5×-1.1×

Profitability

See full
Gross margin22.3%-0.7pp
Operating margin10.7%-1.2pp
Net margin8.1%-0.3pp
FCF margin8.3%+0.3pp

Returns & leverage

See full
Return on equity17.4%-1.3pp
Debt / equity0.5×-0.2×
Current ratio2.3×0.0×

Where this comes from

Reported directly by Hawkins in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The source filing: Hawkins’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 4:15 PM EDT
Fiscal quarter
Q1 FY2027
Calendar quarter
Q2 2026
Accession
0000046250-26-000034
(In thousands)Water TreatmentFood & Health SciencesIndustrial SolutionsTotal
Bulk products (2)16,29612,60228,898
Nutrition37,05737,057
Food24,31024,310
Pharmaceutical6,9656,965
Agricultural27,91427,914
Other1,9601,0041,6704,634
Total external customer sales$158,293$97,250$60,132$315,675
Three months ended June 29, 2025

Item 1. Financial Statements (unaudited):

FAQ

What is Hawkins's pharmaceutical — revenue?
Hawkins (HWKN) reported pharmaceutical — revenue of $6.97M in Q2 2026.
How has Hawkins's pharmaceutical — revenue changed year-over-year?
Hawkins's pharmaceutical — revenue increased by 25.3% year-over-year, from $5.56M to $6.97M.
What is the long-term trend for Hawkins's pharmaceutical — revenue?
Over 2 years (2024 to 2026), Hawkins's pharmaceutical — revenue has grown at a 16.5% compound annual growth rate (CAGR), from $20.55M to $27.87M.
What does pharmaceutical — revenue mean?
This metric represents the total gross sales generated from the company's pharmaceutical product line, encompassing specialized chemical ingredients and solutions for the healthcare and life sciences sectors. It serves as a key indicator of the company's ability to capture market share within the high-value pharmaceutical supply chain and reflects the segment's contribution to overall corporate top-line growth. Monitoring this figure helps investors assess the diversification of the revenue base beyond traditional industrial and water treatment chemical applications.

Ask your AI about Hawkins's pharmaceutical — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude